Preparation and xenotransplantation of porcine islets
First Claim
1. A method of preparing a xenotransplantable porcine islet preparation capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal, the method including or comprising the steps of:
- (i) harvesting the pancreas of piglets at or near full-term gestation;
(ii) extracting pancreatic β
-islet cells from the harvested pancreas, wherein said β
-islet cells (at least at some stage in the performance of the method) are exposed to nicotinamide during at least one stage in the performance of said method; and
(iii) contacting the harvested pancreas or the extracted β
-islet cells with an effective amount of a trauma-protecting anesthetic agent comprising lignocaine.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to developments in the treatment of diabetes in mammals. Particularly it relates to a method of preparing a xenotransplantable porcine islet preparation capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal, the method including or comprising the steps of:
- (I) harvesting the pancreas of piglets at or near full term gestation, and
- (ii) extracting pancreatic β islet cells from the harvested pancreas wherein the islets (at least at some stage in the performance of the method) are exposed to nicotinamide.
Further, the invention relates to a method of encapsulation of a xenotransplantable porcine islet preparation, and transplantation of such a preparation, or a capsule containing such a preparation, into an appropriate recipient mammal.
22 Citations
74 Claims
-
1. A method of preparing a xenotransplantable porcine islet preparation capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal, the method including or comprising the steps of:
-
(i) harvesting the pancreas of piglets at or near full-term gestation; (ii) extracting pancreatic β
-islet cells from the harvested pancreas, wherein said β
-islet cells (at least at some stage in the performance of the method) are exposed to nicotinamide during at least one stage in the performance of said method; and(iii) contacting the harvested pancreas or the extracted β
-islet cells with an effective amount of a trauma-protecting anesthetic agent comprising lignocaine. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
-
17. A method of preparing a xenotransplantable porcine pancreatic β
- -islet cell preparation that is capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal, said method comprising the steps of;
(i) harvesting the pancreas of piglets at or near full-term gestation, (ii) preparing a culture of the pancreatic β
-islet cells;(iii) simultaneously with step (ii) or after step (ii) extracting pancreatic β
-islet cells from said culture of harvested pancreas;(iv) contacting the harvested pancreas or the extracted β
-islet cells with an effective amount of a trauma-protecting anesthetic agent, comprising lignocaine; and(v) encapsulating the extracted pancreatic β
-islet cells with a biocompatible xenotransplantable material, said material being both glucose- and insulin-porous in vivo,wherein said islet cells are contacted with nicotinamide at a time prior to encapsulation in said biocompatible xenotransplantable material. - View Dependent Claims (18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)
- -islet cell preparation that is capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal, said method comprising the steps of;
-
50. A method for producing porcine insulin in a human, said method comprising the steps of:
-
(a) extracting pancreatic β
-islet cells from piglets at or near full-term gestation;(b) simultaneously with, or after (a), treating said β
-islet cells with nicotinamide;(c) encapsulating said β
-islet cells in a biocompatible xenotransplantable material that permits in vivo glucose movement into, and insulin movement out of, said encapsulated β
-islet cells; and(d) injecting or implanting said biocompatible xenotransplantable material comprising said encapsulated β
-islet cells into said human, in an amount effective to produce said porcine insulin in said human,wherein step (a) and/or (c) occurs in the presence of a trauma-protecting agent comprising lignocaine. - View Dependent Claims (51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)
-
Specification